• About
    • Company
    • CEO Message
    • Leadership
    • History
    • Vision & Mission
  • Technology
    • Dual Action Therapy(DAT) Platform
  • Pipeline
    • Pipeline Schedule
  • Clinical Trials
    • Clinical Trials
  • PR/IR
    • Notice
    • Publication
  • Contact
    • Career
    • Contact Us
    • Location
언어선택
  • ENG
  • KOR
  • About
    • Company
    • CEO Message
    • Leadership
    • History
    • Vision & Mission
  • Technology
    • Dual Action Therapy(DAT) Platform
  • Pipeline
    • Pipeline Schedule
  • Clinical Trials
    • Clinical Trials
  • PR/IR
    • Notice
    • Publication
  • Contact
    • Career
    • Contact Us
    • Location
  • PR/IR
  • Notice
PR/IR
SCROLL
  • Notice
  • Publication
Notice
  • NOTICE
    Notice of Completion of the Spin-Off Merger
    12.01.2025
  • NOTICE
    Notice of Capital Reduction and Submission of Share Certificates Pursuant to the Spin-off and Merger
    10.29.2025
  • NOTICE
    Notice of Spin-Off and Merger — Notice to Creditors for Objection and Submission of Share Cert..
    10.29.2025
  • NOTICE
    Announcement of Issuance of New Shares / 신주발행공고
    05.23.2025
  • NOTICE
    Announcement of Issuance of New Shares / 신주발행공고
    04.14.2025
  • NEWS
    L&J BIO, Secured U.S. Patent for Alzheimer's Drug 'AL04'
    10.30.2024
  • NEWS
    L&J BIO "Simultaneous Removal of Two Proteins that causes Dementia"
    08.06.2024
  • NEWS
    [Linked in] L&J BIO’s AAIC 2024 Presentation Video
    08.02.2024
  • NEWS
    L&J BIO to Present Alzheimer’s Treatment at AAIC
    07.24.2024
  • NEWS
    L&J BIO to Present at BIO USA 2024, Initiates Licensing Talks with Leading Global Pharma Firms
    06.24.2024
1 2
L&J BIO
Address
US   25 West Watkins Mill Road Suite C, Gaithersburg, MD 20878, USA

KR   A-711, 712, Beobwon-ro, Songpa-gu, Seoul, 05854, Republic of Korea
TEL

US +1-301-355-4131

KR +82-2-527-8379

E-mail
contact@lnjbio.com

© L&J BIO. All Rights Reserved.